Regulatory Momentum Leverage the FDA Breakthrough designation and robust preclinical validation to position VP.S ENCORE as a credible, faster-to-adopt heart preservation solution. Target transplant centers and organ sharing organizations seeking to improve graft viability and reduce reliance on ice-cold methods.

Strategic Partnerships Capitalize on existing collaborations such as with the Texas Organ Sharing Alliance and SWPDC-funded initiatives to establish pilots and procurement relationships with organ procurement organizations and pediatric centers. Align sales efforts with grant programs to accelerate market access and create reference sites.

Pediatric Expansion Prioritize the portable pediatric heart preservation device as a key growth driver, targeting pediatric transplant programs and regional hospitals with dedicated pediatric research initiatives. Emphasize portability, ease of use, and readiness to differentiate from traditional cold-chain approaches.

Cost Advantage Highlight simplicity, ease of use, and price accessibility as differentiators against larger incumbents. Position VPS as a flexible, lower-cost solution capable of enabling broader adoption in smaller and regional centers and improving procedural efficiency.

Value Messaging Build a compelling ROI narrative around potential improvements in graft viability and reduced cold-chain costs, backed by preclinical results and regulatory credibility. Use this to engage hospital procurement teams and organ procurement organizations with concrete business cases and pilot opportunities.